Skip to main content
. 2015 Aug;6(4):141–148. doi: 10.1177/2042018815595584

Figure 2.

Figure 2.

Patient preference for treatment at week 24.

^p = 0.449/

*Efficacy set consisted of all patients who completed the patient preference questionnaire at the end of the study (N = 60).

**Safety set consisted of all patients who received at least one dose of the study medication during at least one study period and had at least one safety assessment after baseline.